Lécuyer Eric, Herblot Sabine, Saint-Denis Marianne, Martin Richard, Begley C Glenn, Porcher Catherine, Orkin Stuart H, Hoang Trang
Clinical Research Institute of Montreal and from the Departments of Pharmacology, Biochemistry, and Molecular Biology, Université de Montréal, Quebec, Canada.
Blood. 2002 Oct 1;100(7):2430-40. doi: 10.1182/blood-2002-02-0568.
The combinatorial interaction among transcription factors is believed to determine hematopoietic cell fate. Stem cell leukemia (SCL, also known as TAL1 [T-cell acute lymphoblastic leukemia 1]) is a tissue-specific basic helix-loop-helix (bHLH) factor that plays a central function in hematopoietic development; however, its target genes and molecular mode of action remain to be elucidated. Here we show that SCL and the c-Kit receptor are coexpressed in hematopoietic progenitors at the single-cell level and that SCL induces c-kit in chromatin, as ectopic SCL expression in transgenic mice sustains c-kit transcription in developing B lymphocytes, in which both genes are normally down-regulated. Through transient transfection assays and coimmunoprecipitation of endogenous proteins, we define the role of SCL as a nucleation factor for a multifactorial complex (SCL complex) that specifically enhances c-kit promoter activity without affecting the activity of myelomonocytic promoters. This complex, containing hematopoietic-specific (SCL, Lim-only 2 (LMO2), GATA-1/GATA-2) and ubiquitous (E2A, LIM- domain binding protein 1 [Ldb-1]) factors, is tethered to DNA via a specificity protein 1 (Sp1) motif, through direct interactions between elements of the SCL complex and the Sp1 zinc finger protein. Furthermore, we demonstrate by chromatin immunoprecipitation that SCL, E2A, and Sp1 specifically co-occupy the c-kit promoter in vivo. We therefore conclude that c-kit is a direct target of the SCL complex. Proper activation of the c-kit promoter depends on the combinatorial interaction of all members of the complex. Since SCL is down-regulated in maturing cells while its partners remain expressed, our observations suggest that loss of SCL inactivates the SCL complex, which may be an important event in the differentiation of pluripotent hematopoietic cells.
转录因子之间的组合相互作用被认为决定了造血细胞的命运。干细胞白血病(SCL,也称为TAL1 [T细胞急性淋巴细胞白血病1])是一种组织特异性的碱性螺旋-环-螺旋(bHLH)因子,在造血发育中发挥核心作用;然而,其靶基因和分子作用模式仍有待阐明。在这里,我们表明SCL和c-Kit受体在单细胞水平的造血祖细胞中共同表达,并且SCL在染色质中诱导c-kit,因为转基因小鼠中异位SCL表达维持了发育中的B淋巴细胞中c-kit的转录,而在这些细胞中这两个基因通常是下调的。通过瞬时转染实验和内源性蛋白质的免疫共沉淀,我们确定SCL作为多因子复合物(SCL复合物)的成核因子的作用,该复合物特异性增强c-kit启动子活性而不影响髓单核细胞启动子的活性。这个复合物包含造血特异性(SCL、仅含Lim结构域2 [LMO2]、GATA-1/GATA-2)和普遍存在的(E2A、LIM结构域结合蛋白1 [Ldb-1])因子,通过SCL复合物元件与Sp1锌指蛋白之间的直接相互作用,经由特异性蛋白1(Sp1)基序与DNA相连。此外,我们通过染色质免疫沉淀证明SCL、E2A和Sp1在体内特异性地共同占据c-kit启动子。因此,我们得出结论,c-kit是SCL复合物的直接靶标。c-kit启动子的适当激活取决于复合物所有成员的组合相互作用。由于SCL在成熟细胞中下调而其伙伴仍保持表达,我们的观察结果表明SCL的缺失使SCL复合物失活,这可能是多能造血细胞分化中的一个重要事件。